Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis

被引:58
作者
Atkins, GJ
Bouralexis, S
Evdokiou, A
Hay, S
Labrinidis, A
Zannettino, ACW
Haynes, DR
Findlay, DM
机构
[1] Univ Adelaide, Dept Orthopaed & Trauma, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[3] Univ Adelaide, Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia
[4] Univ Adelaide, Dept Pathol, Adelaide, SA 5000, Australia
基金
英国医学研究理事会;
关键词
human osteoblasts; Apo2L/TRAIL; receptors; apoptosis; caspase; chemotherapy;
D O I
10.1016/S8756-3282(02)00858-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apo2 ligand (Apo2L/TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. Apo2L/TRAIL can selectively induce programmed cell death in transformed cells, although its wide tissue distribution suggests potential physiological roles. We have investigated the expression, in human osteoblast-like cells (NHBC), of Apo2L/TRAIL and the known Apo2L/TRAIL death receptors, DR4 and DR5, and the Apo2L/TRAIL decoy receptors, DcR-1, DcR-2, and osteoprotegerin (OPG). NHBC expressed abundant mRNA corresponding to each of these molecular species. Immunofluorescence staining demonstrated that Apo2L/TRAIL protein was abundant within the cytoplasm of NHBC and OPG was strongly expressed at the cell surface. DR5 and DcR-2 were present in the cell membrane and cytoplasm and DcR-1 was confined to the nucleus. DR4 staining was weak. Neither Apo2L/TRAIL alone, nor in combination with chemotherapeutic agents of clinical relevance to treatment of osteogenic sarcoma, induced cell death in NRBC, as assessed morphologically and by activation of caspase-3. In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. In NHBC, we observed strong associations between the levels of mRNA corresponding to the pro-apoptotic molecules, Apo2L/TRAIL, DR4, and DR5, and those corresponding to prosurvival molecules, DcR-1, DcR-2, OPG, and FLIP, suggesting that the balance between pro-survival and pro-apoptotic molecules is a mechanism by which NHBC can resist Apo2L/TRAIL-mediated apoptosis. In contrast, osteogenic sarcoma cells had low or absent levels of DcR-1 and DcR-2. These results provide a foundation to explore the role of Apo2L/TRAIL in osteoblast physiology. In addition, they predict that therapeutic use of recombinant Apo2L/TRAIL, in combination with chemotherapeutic agents to treat skeletal malignancies, would have limited toxic effects on normal osteoblastic cells.
引用
收藏
页码:448 / 456
页数:9
相关论文
共 44 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[3]   Expression of osteoclast differentiation signals by stromal elements of giant cell tumors [J].
Atkins, GJ ;
Haynes, DR ;
Graves, SE ;
Evdokiou, A ;
Hay, S ;
Bouralexis, S ;
Findlay, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) :640-649
[4]   Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone [J].
Atkins, GJ ;
Bouralexis, S ;
Haynes, DR ;
Graves, SE ;
Geary, SM ;
Evdokiou, A ;
Zannettino, ACW ;
Hay, S ;
Findlay, DM .
BONE, 2001, 28 (04) :370-377
[5]   Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].
Chaudhary, PM ;
Eby, M ;
Jasmin, A ;
Bookwalter, A ;
Murray, J ;
Hood, L .
IMMUNITY, 1997, 7 (06) :821-830
[6]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[7]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170
[8]   Cyclooxygenase-2: a novel target for cancer chemotherapy? [J].
Dempke, W ;
Rie, C ;
Grothey, A ;
Schmoll, HJ .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (07) :411-417
[9]   Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].
Emery, JG ;
McDonnell, P ;
Burke, MB ;
Deen, KC ;
Lyn, S ;
Silverman, C ;
Dul, E ;
Appelbaum, ER ;
Eichman, C ;
DiPrinzio, R ;
Dodds, RA ;
James, IE ;
Rosenberg, M ;
Lee, JC ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367
[10]   Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRIAL-induced apoptosis [J].
Evdokiou, A ;
Bouralexis, S ;
Atkins, GJ ;
Chai, F ;
Hay, S ;
Clayer, M ;
Findlay, DM .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) :491-504